One of the small-cap pharma stocks engaged in manufacturing and exporting PCR-based molecular diagnostic kits, PCR enzymes & PCR reagents, and agrochemical-based products. The stock has jumped by an intraday high of 19.65 percent after reporting September quarter results in 2024. The company’s revenue increased by 51.98 percent to Rs. 29.15 crore, and net profit increased by 86.62 percent to Rs. 14.65 crore.
Stock movement
With a market capitalization of Rs. 1,458.20 crores, the shares of 3B Blackbio DX Limited intraday a high at Rs. 1,910 per equity share, rising nearly around 19.65 percent from its previous day’s close price of Rs. 1,596.35. Since then, the share has retreated and is now trading at Rs. 1,694.90
Q2 FY25 Result Walkthrough
Coming into the quarterly results of 3B Blackbio DX Limited, the company’s consolidated revenue from operations increased by 51.98 percent YOY, from Rs. 19.18 crore in Q2 FY24 to Rs. 29.15 crore in Q2 FY25, and grew by 26.08 percent QoQ from Rs. 23.12 crore in Q1 FY25.
Further, the company’s EBITDA has increased by 82.06 percent, from Rs. 10.6 crore in Q2 FY24 to Rs. 19.29 crore in Q2 FY25.
In Q2 FY25, 3B Blackbio DX Limited’s consolidated net profit slightly increased by 86.62 percent YOY, reaching Rs. 14.65 crore compared to Rs. 7.85 crore during the same period last year. As compared to Q1 FY25, the net profit has increased by 29.65 percent, from Rs. 11.3 crore.
The basic earnings per share increased by 25.34% and stood at Rs 17.35 as against Rs 13.19 recorded in the previous quarter FY25.
In terms of return ratios, 3B Blackbio DX Limited’s share ROE and ROCE are currently at 15.4 percent and 21 percent, respectively. 3B Blackbio DX Limited has a debt-to-equity ratio of 0.004x, which shows the company is almost debt-free
Also read…
Shareholding pattern
In September 2024, 3B BlackBio Dx Limited had a majority stake held by the promoters at 41.28 percent, foreign institutional investors at 3.27 percent, domestic institutional investors at 1.96 percent, and the public at 53.48 percent.
Products Offering
3B BlackBio Dx Limited specializes in PCR-based molecular diagnostic kits, including TRUPCR® for oncology and infectious diseases, TRURAPID® lateral flow assays, and
TRUNGS® next-generation sequencing assays. The company also provides PCR enzymes, reagents, and extraction kits.
Company Overview
3B Blackbio DX Limited was established in 2011 and is headquartered in Bhopal, Madhya Pradesh, India. The company is a prominent Indian biotechnology company specializing in PCR-based molecular diagnostic kits. It operates under ISO 13485:2016 certification, ensuring compliance with international quality standards for medical devices. Written By – Nikhil Naik
written by – Nikhil
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
Start Your Stock Market Journey Today!
Want to learn Stock Market trading and Investing? Make sure to check out exclusive Stock Market courses by FinGrad, the learning initiative by Trade Brains. You can enroll in FREE courses and webinars available on FinGrad today and get ahead in your trading career. Join now!!
